๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics, and effect

โœ Scribed by Russell K. Portenoy; Jeremy Miransky; Howard T. Thaler; Joy Hornung; Cynthia Bianchi; Irene Cibas-Kong; Edward Feldhamer; Frank Lewis; Iliana Matamoros; Marian Z. Sugar; Allan P. Olivieri; Nancy E. Kemeny; Kathleen M. Foley


Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
800 KB
Volume
70
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis


Background:

Few studies have evaluated the epidemiology and effect of pain in ambulatory patients with cancer who are undergoing active therapy. this information is needed to develop strategies for supportive care in this population.

Methods:

The prevalence and characteristics of pain were determined in a prospective survey of ambulatory patients with lung or colon cancer. to reduce bias and acquire comprehensive information, the methodology used face-to-face interviews by trained quality assurance analysts, a multifaceted assessment instrument, and multivariate statistical analysis.

Results:

In a telephone interview, "persistent or frequent" pain during the previous 2 weeks was reported by 57 of 145 (39.3%) patients with lung cancer and 52 of 181 (28.7%) patients with colon cancer; 91 of these patients (47 lung and 44 colon) were interviewed in detail. all patients had excellent performance status, and with the exception of pain location, there were no significant differences between the two tumor types. one-third of the patients had more than one discrete pain. median pain duration was 4 weeks (range, less than 1 week-468 weeks), and average pain intensity was moderate. approximately 90% of patients experienced pain more than 25% of the time. pain interfered moderately or more with general activity and work in approximately half of the patients; more than half reported moderate or greater pain interference in sleep, mood, and enjoyment of life. multiple regression analysis revealed that the daily frequency of pain, the intensity of the worst pain, the score on a mood scale, and the frequency of the worst pain accounted for 58.7% of the variance in average pain intensity. likewise, 52.1% of the variance in a derived measure of pain interference in function was explained by the mood score, frequency of the worst pain, number of pains, and pain intensity.

Conclusions:

These data indicate that pain is prevalent among well-functioning ambulatory patients and substantially compromises function in approximately half of the patients who experience it. pain is a complex symptom; aspects other than intensity, such as frequency, strongly influence its effect.


๐Ÿ“œ SIMILAR VOLUMES


Serum KL-6 levels in lung cancer patient
โœ Kunihiko Miyazaki; Koichi Kurishima; Katsunori Kagohashi; Mio Kawaguchi; Hiroich ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 90 KB

## Abstract __Background__: It is not known whether lung cancer patients with interstitial lung disease (ILD) might have higher serum levels of KLโ€6, a high molecular weight glycoprotein classified as a polymorphic epithelial mucin. In addition, prognosis of these patients with elevated serum KLโ€6

K-ras mutation in sputum of patients wit
โœ Ze'ev Ronai; Marina S. Yabubovskaya; Edith Zhang; Gennady A. Belitsky ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 493 KB ๐Ÿ‘ 2 views

K-ras mutation appears in about 60% of patients with non-small-cell lung cancer (NSCLC). This freqLency and its presence in normal appearing tissues point to the potential of ras oncogene mutation to serve as a good biomarker. Using enriched PCR (EPCR), which enables the detection of one mutant alle

Prevalence of the rhesus-negative phenot
โœ T. Cerny; M. F. Fey; R. Oppliger; M. Castiglione; B. Nachbur; M. Gertsch; A. Gas ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 380 KB

We report that the Rhesus (Rh)-negative phenotype is more prevalent in patients with small-cell lung cancer (SCLC) than in the normal Caucasian population (SCLC: 25% Rh-negative vs. 15% expected, p < 0.000 I). This finding has been validated for a Central and a Northern European population (Switzerl